bismuth-213 anti-human PD-L1 monoclonal antibody

Bismuth-213 anti-human PD-L1 monoclonal antibody is a preclinical targeted alpha-particle therapy (TAT) radioconjugate. It consists of a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), specifically the commercial clone 29E.2A3, conjugated to the alpha-emitting radionuclide bismuth-213 (213Bi) via a chelator (such as CHX-A''-DTPA). By binding to PD-L1 expressed on tumor cells and immunosuppressive cells in the tumor microenvironment, the radioconjugate delivers highly localized, high-energy alpha radiation, inducing double-strand DNA breaks and immunogenic cell death. This agent has been investigated in preclinical models of human melanoma, both as a monotherapy and in combination with adoptive cell transfer of PD-1-deficient T cells, demonstrating significant tumor growth delay and survival benefits with minimal systemic toxicity.

Other names

213Bi-anti-hPD-L1 mAb213Bi-anti-human-PD-L1 mAb213Bi-anti-PD-L1 mAbbismuth-213 anti-PD-L1 monoclonal antibodybismuth213 anti-PD-L1 monoclonal antibodybismuth 213 anti-PD-L1 monoclonal antibodybismuth-213 anti-programmed death-ligand 1 monoclonal antibodybismuth213 anti-programmed death-ligand 1 monoclonal antibodybismuth 213 anti-programmed death-ligand 1 monoclonal antibody